Earnings Releases·Nov 13, 2026, 8:02 AM ET

Benitec Biopharma — First Quarter 2027 Fiscal-Year Earnings Summary

Total expenses rose 48% year-over-year to $14.5 million, driven by a 153% increase in R&D costs to $8.6 million, resulting in a net loss of $12.9 million ($0.26 per share) compared to $9.0 million ($0.22 per share) in the prior year quarter.
The company remains on track to finalize the pivotal study design for lead candidate BB-301 in Q1 2027 and initiate the pivotal trial in mid-2027, following interim Phase 1b/2a results showing a 100% responder rate with no serious adverse events.
Cash and cash equivalents decreased to $176.5 million as of September 30, 2026, from $179.972 million in June 2026, while the company announced a fiscal year-end transition from June 30 to December 31.
Management expressed strengthened conviction in BB-301's potential based on consistent clinical benefits, noting the asset is the first and only disease-modifying genetic medicine in development for OPMD-related dysphagia.